ONCRUZO Trademark

Trademark Overview

On Monday, November 11, 2013, a trademark application was filed for ONCRUZO with the United States Patent and Trademark Office. The USPTO has given the ONCRUZO trademark a serial number of 86115243. The federal status of this trademark filing is CANCELLED - SECTION 7 as of Thursday, May 21, 2020. This trademark is owned by Celgene Corporation. The ONCRUZO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease and cancer
oncruzo

General Information

Serial Number86115243
Word MarkONCRUZO
Filing DateMonday, November 11, 2013
Status711 - CANCELLED - SECTION 7
Status DateThursday, May 21, 2020
Registration Number4559840
Registration DateTuesday, July 1, 2014
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 15, 2014

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease and cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code1 - Sec. 7(d) - Entire Registration
Class Status DateThursday, May 21, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Friday, November 22, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 3, 2014ASSIGNED TO EXAMINER
Monday, February 3, 2014NON-FINAL ACTION WRITTEN
Monday, February 3, 2014NON-FINAL ACTION E-MAILED
Monday, February 3, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 12, 2014ASSIGNED TO LIE
Monday, February 24, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, November 14, 2013NEW APPLICATION ENTERED
Thursday, November 14, 2013TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, November 14, 2013TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Tuesday, February 4, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 21, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 21, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 24, 2014SUSPENSION LETTER WRITTEN
Monday, February 24, 2014LETTER OF SUSPENSION E-MAILED
Wednesday, December 3, 2014CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Tuesday, July 28, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 24, 2014TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, March 3, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 3, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 3, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 8, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 26, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 15, 2014PUBLISHED FOR OPPOSITION
Tuesday, April 15, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 1, 2014REGISTERED-PRINCIPAL REGISTER
Monday, May 11, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, July 1, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, April 10, 2020REQUEST FOR SECT 7 TOTAL SURRENDER FILED
Friday, April 10, 2020TEAS SECTION 7 SURRENDER RECEIVED
Thursday, May 21, 2020CANCELLED SECTION 7-TOTAL
Friday, May 22, 2020NOTICE OF CANCELLATION SEC. 7 SURRENDER EMAILED

Related Keywords

oncruzo pharmaceutical preparations treatment blood disease cancer system modulate namely cytokine